In an interview with ONCOLOGY®, Douglas Braun, CSP, PharmD, RPh, offers a comprehensive review of real-world treatment considerations of umbralisib as therapy for patients with previously treated follicular and marginal zone lymphoma.
Douglas Braun, CSP, PharmD, RPh
Advertisement
Articles by Douglas Braun, CSP, PharmD, RPh
Advertisement
Latest Updated Articles
Expert Commentary on the Product Profile of Umbralisib for LymphomaPublished: October 17th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
4
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
5
